OUR FIRM

Latest News

March 20, 2019

Dana Flanders Joins Guggenheim Securities as Therapeutics Analyst

NEW YORK – Guggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Dana Flanders will join the firm in May as a Director in a planned expansion of the Healthcare research team. Mr. Flanders will focus on the coverage of specialty pharmaceutical and biotech companies, working closely with the firm’s growing therapeutics group.

Mr. Flanders will join Guggenheim most recently from Goldman Sachs, where he was a senior equity research analyst and Vice President covering specialty and small-to-mid-cap biopharmaceutical companies. Prior to Goldman Sachs, he covered specialty pharmaceutical companies as an equity research analyst at J.P. Morgan. Previously, he worked at Canaccord Genuity covering specialty pharmaceuticals.

“Dana will be an excellent addition to our research team,” said Stefano Natella, Co-Head of Equities at Guggenheim Securities. “His expertise in the specialty pharmaceutical sector complements the deep roster of talent we have assembled in the healthcare space. I look forward to his future successes at Guggenheim.”

Over the past two years, Guggenheim has significantly expanded its Healthcare research team, which now includes analysts Seamus Fernandez, Michael Schmidt, Whitney Ijem, Yatin Suneja, Etzer Darout, Adnan Butt, Glen Santangelo, Dave Westenberg, and Chris Pasquale.

Mr. Flanders is a CFA Charterholder and received his B.A. from Cornell University. He will be based in Guggenheim’s New York office.


About Guggenheim Securities

Guggenheim Securities is the investment banking and capital markets business of Guggenheim Partners, a global investment and advisory firm. Guggenheim Securities offers services that fall into four broad categories: Advisory, Financing, Sales and Trading, and Research. Guggenheim Securities is headquartered in New York, with additional offices in Chicago, Boston, Atlanta, San Francisco, and Houston. For more information, please contact us at GSinfo@GuggenheimPartners.com or 212.518.9200.


About Guggenheim Partners

Guggenheim Partners is a global investment and advisory firm with more than $265 billion1 in assets under management. Across our three primary businesses of investment management, investment banking, and insurance services, we have a track record of delivering results through innovative solutions. With over 2,400 professionals based in offices around the world, our commitment is to advance the strategic interests of our clients and to deliver long-term results with excellence and integrity. We invite you to learn more about our expertise and values by visiting GuggenheimPartners.com and following us on Twitter at twitter.com/guggenheimptnrs.


Media Contact

Ellen Cunningham
Guggenheim Partners
212.518.9578
Ellen.N.Cunningham@GuggenheimPartners.com

 

1Assets under management are as of 12.31.2018 and include consulting services for clients whose assets are valued at approximately $67bn.



June 11, 2021

Guggenheim Partners Appoints Gerald Donini A Managing Partner

NEW YORK, NY – Guggenheim Partners, the global financial services firm, today named its Chief Operating Officer, Gerald Donini, a Managing Partner of the firm.

Read More

May 21, 2021

Benjamin Wilson Joins Guggenheim Securities as Senior Managing Director in its Mergers & Acquisitions Advisory Practice

NEW YORK, NYGuggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Benjamin Wilson has joined the firm as a Senior Managing Director in its Mergers & Acquisitions advisory practice. Mr. Wilson is based out of Guggenheim’s New York office.

Read More

May 17, 2021

Guggenheim Securities Hires Dino Dedić to Expand Healthcare Investment Banking Practice

NEW YORK, NYGuggenheim Securities, the investment banking and capital markets division of Guggenheim Partners, announced today that Dino Dedić has joined the firm as a Senior Managing Director to expand coverage in its healthcare investment banking group. Mr. Dedić will focus on advising companies in the pharmaceutical services and animal health sectors.

Read More